↓ Skip to main content

Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis

Overview of attention for article published in Arthritis Research & Therapy, June 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

twitter
6 tweeters

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis
Published in
Arthritis Research & Therapy, June 2016
DOI 10.1186/s13075-016-1015-0
Pubmed ID
Authors

Padmanabha D. Shenoy, Manish Bavaliya, Sujith Sashidharan, Kaveri Nalianda, Sreelakshmi Sreenath

Abstract

Scleroderma is a systemic autoimmune disease characterized mainly by skin manifestations and involvement of various visceral organs, especially the lungs. Lung involvement is the leading cause of mortality in patients with scleroderma. There are data to suggest that cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are effective in the management of scleroderma interstitial lung disease (SSc-ILD) but no head to head comparative data are available to date. For the last 3 years, patients with SSc-ILD have been treated at our centre by protocol-based administration of intravenous CYC and MMF. Results of lung function tests (spirometry) were recorded at baseline, 3 months and 6 months in every patient. The clinical records of patients with systemic sclerosis and significant ILD, who were not previously exposed to any immunosuppressant and were treated with MMF OR CYC, were reviewed. The efficacy of treatment was assessed by the change in forced vital capacity on spirometry. Of the total 57 patients included in the analysis, 34 were treated with MMF and 23 were treated with CYC. Mean duration of illness was 4.19 ± 2.82 years in the MMF and 6.04 ± 5.96 years in the CYC group. After 6 months of therapy, FVC increased by 10.84 ± 13.81 % in the CYC group and by 6.07 ± 11.92 % in the MMF group. This improvement from baseline was statistically significant in both groups (P < 0.01). The improvement was comparable with no statistically significant differences between groups (P = 0.373). There were no major adverse events reported in either arm. Both MMF and CYC were equally effective in stabilizing lung function in patients with scleroderma and ILD.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 12 23%
Researcher 9 17%
Other 5 10%
Student > Bachelor 3 6%
Student > Doctoral Student 3 6%
Other 11 21%
Unknown 9 17%
Readers by discipline Count As %
Medicine and Dentistry 38 73%
Immunology and Microbiology 1 2%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Engineering 1 2%
Unknown 11 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2016.
All research outputs
#3,766,231
of 13,855,981 outputs
Outputs from Arthritis Research & Therapy
#941
of 2,235 outputs
Outputs of similar age
#77,404
of 265,599 outputs
Outputs of similar age from Arthritis Research & Therapy
#1
of 2 outputs
Altmetric has tracked 13,855,981 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,235 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,599 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them